Longeveron Inc. (LGVN)
1.77
-0.04 (-2.21%)
At close: Jan 15, 2025, 12:29 PM
undefined% (undefined)
| Bid | 1.76 |
| Market Cap | 26.26M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.62 |
| PE Ratio (ttm) | -0.31 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.77 |
| Volume | 151,662 |
| Avg. Volume (20D) | 470,003 |
| Open | 1.78 |
| Previous Close | 1.81 |
| Day's Range | 1.71 - 1.79 |
| 52-Week Range | 0.77 - 11.00 |
| Beta | undefined |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 23
Stock Exchange NASDAQ
Ticker Symbol LGVN
Website https://www.longeveron.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LGVN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 464.97% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Longeveron Inc. is scheduled to release its earnings on Feb 25, 2025,
during market hours.
Analysts project revenue of $660.00K, reflecting a 947.62% YoY growth and earnings per share of -0.36, making a -85.60% decrease YoY.
Analysts project revenue of $660.00K, reflecting a 947.62% YoY growth and earnings per share of -0.36, making a -85.60% decrease YoY.
5 months ago ·
Source
+0.87%
Longeveron shares are trading higher after the com...
Unlock content with
Pro Subscription
6 months ago ·
Source
-16.67%
Longeveron shares are trading lower after the company announced a $9.0 million registered direct offering of 2.2 million shares of its common stock at $4.025 per share.
